Literature DB >> 17555795

Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.

Ryosuke Osada1, Akiko Horiuchi, Norihiko Kikuchi, Junko Yoshida, Akiko Hayashi, Masao Ota, Yoshihiko Katsuyama, Giovanni Melillo, Giovanni Mellilo, Ikuo Konishi.   

Abstract

The hypoxia-inducible factor (HIF) is a transcriptional factor with important roles in tumor biology. To clarify the possible involvement of the HIF-alpha subunit and von Hippel-Lindau (VHL) protein in the development and progression of ovarian carcinoma, we analyzed the immunohistochemical expressions of HIF-1alpha, HIF-2alpha, and VHL in 107 cases of epithelial ovarian tumors. In addition, we examined loss of heterozygosity (LOH) at VHL gene loci. The frequency of the cytoplasmic expression of HIF-2alpha in carcinomas was higher than that in benign and borderline tumors (P < .0001). Furthermore, the nuclear expression of HIF-1alpha and the cytoplasmic expression of HIF-2alpha were significantly higher in tumors of FIGO (International Federation of Gynecology and Obstetrics) stages III and IV than in those of stages I and II. On the other hand, the cytoplasmic expression of HIF-1alpha did not show differences among histological malignancies. There was a positive correlation between nuclear HIF-1alpha expression and vascular endothelial growth factor (rho = 0.320, P < .001). Although LOH at the VHL gene locus was frequent in ovarian carcinomas (24%), there is no significant correlation between LOH and loss of VHL expression. In 22 clear cell carcinomas, VHL expression showed a significantly negative correlation with the nuclear expression of HIF-1alpha (rho = -0.529, P = .0153). The log-rank test showed that nuclear positive immunostaining for HIF-1alpha (P = .002) and cytoplasmic positive immunostaining for HIF-2alpha (P = .0112) in tumor cells are associated with poor prognosis of patients with ovarian carcinoma. Multivariate analysis also showed that the nuclear expression of HIF-1alpha is an independent prognostic factor. These results show that the HIF-alpha subunit represents an important biomarker in the evaluation of the prognosis of patients with ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555795     DOI: 10.1016/j.humpath.2007.02.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  46 in total

1.  Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

Authors:  S John Weroha; Ann L Oberg; Katie L Allen Ziegler; Shaker R Dakhilm; Kendrith M Rowland; Lynn C Hartmann; Dennis F Moore; Gary L Keeney; Prema P Peethambaram; Paul Haluska
Journal:  Gynecol Oncol       Date:  2011-04-22       Impact factor: 5.482

Review 2.  Relationship between Volatile Anesthetics and Tumor Progression: Unveiling the Mystery.

Authors:  Bo Jiao; Chun Yang; Nian-Nian Huang; Ning Yang; Jia Wei; Hui Xu
Journal:  Curr Med Sci       Date:  2018-12-07

3.  Pathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis.

Authors:  Yue Jin; Haolu Wang; Xiaowen Liang; Jun Ma; Yu Wang
Journal:  Tumour Biol       Date:  2014-05-21

4.  Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.

Authors:  Colles Price; Stanley Gill; Zandra V Ho; Shawn M Davidson; Erin Merkel; James M McFarland; Lisa Leung; Andrew Tang; Maria Kost-Alimova; Aviad Tsherniak; Oliver Jonas; Francisca Vazquez; William C Hahn
Journal:  Cancer Res       Date:  2019-03-21       Impact factor: 12.701

Review 5.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

6.  Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma.

Authors:  Laura M S Seeber; Nicole Horrée; Petra van der Groep; Elsken van der Wall; René H M Verheijen; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-06-19       Impact factor: 4.430

7.  Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.

Authors:  Lei Huang; Qilin Ao; Qinghua Zhang; Xiaokui Yang; Hui Xing; Fang Li; Gang Chen; Jianfeng Zhou; Shixuan Wang; Gang Xu; Li Meng; Yunping Lu; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

8.  Role and mechanism of hypoxia-inducible factor-1 in cell growth and apoptosis of breast cancer cell line MDA-MB-231.

Authors:  Yonghong Shi; Miaomiao Chang; Fang Wang; Xiaohui Ouyang; Yongfeng Jia; Hua DU
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

9.  An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kozue Suzuki; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-08-05       Impact factor: 4.064

10.  Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.

Authors:  William M Merritt; Christopher G Danes; Mian M K Shahzad; Yvonne G Lin; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Lingegowda S Mangala; Rebecca L Stone; Hye Sun Kim; David M Gershenson; Robert B Jaffe; Robert L Coleman; Joya Chandra; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2009-08-13       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.